کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
6013095 | 1185909 | 2013 | 6 صفحه PDF | دانلود رایگان |
![عکس صفحه اول مقاله: Cost-effectiveness analysis of antiepileptic drugs in the treatment of Lennox-Gastaut syndrome Cost-effectiveness analysis of antiepileptic drugs in the treatment of Lennox-Gastaut syndrome](/preview/png/6013095.png)
- Economic model evaluated costs/outcomes of clobazam as adjunctive therapy for LGS.
- Percentage of medically attended drop seizures was a driver of model results.
- Clobazam was more efficacious/less costly vs. lamotrigine/rufinamide/topiramate.
- Clobazam leads to lower costs via reduction in medically attended drop seizures.
An economic model evaluated the costs and outcomes of adjunctive clobazam therapy for Lennox-Gastaut syndrome (LGS) compared with adjunctive lamotrigine, rufinamide, and topiramate. Clinical data were used to estimate baseline frequency and the percentage of drop-seizure reductions over 3Â months (all comparators) and 2Â years (rufinamide). Claims data from a large US health care plan were employed to estimate costs. After 3Â months, 21.5% of those receiving clobazam were drop-seizure-free. Over a 3-month horizon, clobazam was more effective and less expensive than comparators, with the assumption that >Â 0.77% of drop seizures required medical care. Below this threshold, topiramate was less costly than clobazam. With the base-case assumption that 2.3% of drop seizures were medically attended, costs for patients receiving clobazam totaled $30,147 versus $34,223-$35,378 for comparators. Clobazam was more efficacious and less costly than rufinamide over a 2-year horizon. The percentage of medically attended drop seizures was a driver of results. Clobazam treatment may be cost-saving.
Journal: Epilepsy & Behavior - Volume 29, Issue 1, October 2013, Pages 184-189